Bimekizumab Efficacy by Prior Biologic Treatment in Patients with Moderate to Severe Hidradenitis Suppurativa: 48-Week Pooled Data from the Randomized, Double-Blind, Placebo-Controlled, Multicenter BE HEARD I and II Phase 3 Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 1, p. s349, 2024. DOI: 10.25251/skin.8.supp.349. Disponível em: https://skin.dermsquared.com/skin/article/view/2449. Acesso em: 14 may. 2025.